Generic Name: lenalidomide
Drug Name: Revlimid®

The list of clinical trials will be updated if additional studies are conducted, approved, and meet criteria for posting as explained in the Celgene Clinical Trial Data Sharing Policy.

Unique ID	Indication / Disease	Phase	Title of Study	Synopsis
CC-5013-MM-009 Alternate ID: NCT00056160	Multiple Myeloma –	Phase 3	A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
CC-5013-MM-010 Alternate ID: NCT00424047	Multiple Myeloma –	Phase 3	A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
CC-5013-MM-015 Alternate ID: NCT00405756 EudraCT 2006-001865-41	Multiple Myeloma–	Phase 3	A Phase III, Multicentre, Randomized, Randomised, Double-blind, Placebo-controlled, 3-Arm Parallel-group Study to Determine the Efficacy and Safety of Lenalidominde (Revlimid®) in Combination With Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects With Newly Diagnosed Multiple Myeloma Who are 65 Years Of Age or Older
CC-5013-MM-020 Alternate ID: NCT00689936 EudraCT 2007-004823-39	Multiple Myeloma –	Phase 3	A Phase III, Randomized, Open-Label, 3-Arm Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid®) Plus Low-Dose Dexamethasone When Given Until Progressive Disease or for 18 Four-Week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-Week Cycles in Subjects With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation
CC-5013-MM-021 Alternate ID: NCT01593410	Multiple Myeloma –	Phase 2	A multicenter, open-label Phase 2 study to determine the efficacy and safety of lenalidomide plus low-dose dexamethasone in Chinese subjects with relapsed/refractory multiple myeloma(RRMM)